Report
Verastem’s KRAS G12D inhibitor shows a 50% response rate among eight pancreatic cancer patients
STAT reports the Phase 1/2 result came from patients with metastatic disease receiving the drug as second-line therapy.
TLDR
STAT reports that Verastem Oncology’s KRAS G12D inhibitor produced a 50% response rate among eight patients with metastatic pancreatic cancer receiving it as second-line therapy in a Phase 1/2 trial. STAT also says Verastem is studying the drug in more than 200 patients with advanced solid tumors, including non-small cell lung cancer.
Combined views
1K
1 Source, first seen ago